Cerebrospinal Fluid Tau and β-Amyloid: How Well Do These Biomarkers Reflect Autopsy-Confirmed Dementia Diagnoses?

Clinical diagnosis of Alzheimer's disease: Report of the NINCDS‐ADRDA Work Group* under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease

McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915 · see citing works

Comparing the Areas under Two or More Correlated Receiver Operating Characteristic Curves: A Nonparametric Approach

DeLong, E. R., DeLong, D. M., & Clarke-Pearson, D. L. (1988) · Biometrics · doi:10.2307/2531595 · Cited by 22,649 · see citing works

Peripherally administered antibodies against amyloid β-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease

Bard, F., Cannon, C., Barbour, R., Burke, R.-L., Games, D., Grajeda, H., Guido, T., Hu, K., Huang, J., Johnson-Wood, K., et al. (2000) · Nature Medicine · doi:10.1038/78682 · Cited by 2,012 · see citing works

An Increased Percentage of Long Amyloid β Protein Secreted by Familial Amyloid β Protein Precursor (βApp ₇₁₇ ) Mutants

Suzuki, N., Cheung, T. T., Cai, X.-D., Odaka, A., Otvos, L., Eckman, C., Golde, T. E., & Younkin, S. G. (1994) · Science · doi:10.1126/science.8191290 · Cited by 1,471 · see citing works

Consensus Report of the Working Group on: “Molecular and Biochemical Markers of Alzheimer’s Disease”

The Ronald and Nancy Reagan Research Institute of the Alzheimer’s Association and, & National Institute on Aging Working Group (1998) · Neurobiology of Aging · doi:10.1016/s0197-4580(98)00022-0 · Cited by 702 · see citing works

Reduction of β‐amyloid peptide₄₂ in the cerebrospinal fluid of patients with Alzheimer's disease

Motter, R., Vigo‐Pelfrey, C., Kholodenko, D., Barbour, R., Johnson‐Wood, K., Galasko, D., Chang, L., Miller, B., Clark, C., Green, R., et al. (1995) · Annals of Neurology · doi:10.1002/ana.410380413 · Cited by 701 · see citing works

The 14-3-3 Brain Protein in Cerebrospinal Fluid as a Marker for Transmissible Spongiform Encephalopathies

Hsich, G. E., Kenney, K., Gibbs, C. J., Lee, K. H., & Harrington, M. G. (1996) · New England Journal of Medicine · doi:10.1056/nejm199609263351303 · Cited by 657 · see citing works

Plasma and Cerebrospinal Fluid Levels of Amyloid β Proteins 1-40 and 1-42 in Alzheimer Disease

Mehta, P. D., Pirttilä, T., Mehta, S. P., Sersen, E. A., Aisen, P. S., & Wisniewski, H. M. (2000) · Archives of Neurology · doi:10.1001/archneur.57.1.100 · Cited by 582 · see citing works

Evaluation of CSF-tau and CSF-Aβ42 as diagnostic markers for Alzheimer disease in clinical practice

Andreasen, N., Minthon, L., Davidsson, P., Vanmechelen, E., Vanderstichele, H., Winblad, B., & Blennow, K. (2001) · Archives of Neurology · doi:10.1001/archneur.58.3.373 · Cited by 573 · see citing works

Quantification of tau phosphorylated at threonine 181 in human cerebrospinal fluid: a sandwich ELISA with a synthetic phosphopeptide for standardization

Vanmechelen, E., Vanderstichele, H., Davidsson, P., Kerschaver, E. V., Perre, B. V. D., Sjögren, M. J. C., Andreasen, N. C., & Blennow, K. (2000) · Neuroscience Letters · doi:10.1016/s0304-3940(00)01036-3 · Cited by 487 · see citing works

Clinico‐Neuropathological Correlation of Alzheimer's Disease in a Community‐Based Case Series

Lim, A., Tsuang, D. W., Kukull, W. A., Nochlin, D., Leverenz, J. B., McCormick, W. C., Bowen, J., Teri, L. L., Thompson, J. C., Peskind, E. R., et al. (1999) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.1999.tb02571.x · Cited by 450 · see citing works

Transient increase in total tau but not phospho-tau in human cerebrospinal fluid after acute stroke

Hesse, C., Rosengren, L., Andreasen, N., Davidsson, P., Vanderstichele, H., Vanmechelen, E., & Blennow, K. (2001) · Neuroscience Letters · doi:10.1016/s0304-3940(00)01697-9 · Cited by 450 · see citing works

Amyloid-β immunotherapy for Alzheimer's disease: the end of the beginning

Schenk, D. (2002) · Nature Reviews Neuroscience · doi:10.1038/nrn938 · Cited by 436 · see citing works

THE 14-3-3 BRAIN PROTEIN IN CEREBROSPINAL FLUID AS A MARKER FOR TRANSMISSIBLE SPONGIFORM ENCEPHALOPATHIES

Sich, G. A. H., Enney, K. I. K., Ibbs, C. L. J. G., Ee, K., & Arrington, G. H. (1996) · Cited by 380 · see citing works

The Molecular and Genetic Basis of Neurological Disease

Trojanowski, J. Q. (1993) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/00005072-199309000-00013 · Cited by 341 · see citing works

Elevated levels of tau-protein in cerebrospinal fluid of patients with Creutzfeldt–Jakob disease

Otto, M., Wiltfang, J., Tumani, H., Zerr, I., Lantsch, M., Kornhuber, J., Weber, T., Kretzschmar, H. A., & Poser, S. (1997) · Neuroscience Letters · doi:10.1016/s0304-3940(97)00215-2 · Cited by 339 · see citing works

Tau protein and 14-3-3 protein in the differential diagnosis of Creutzfeldt–Jakob disease

Otto, M., Wiltfang, J., Cepek, L., Neumann, M., Mollenhauer, B., Steinacker, P., Ciesielczyk, B., Schulz‐Schaeffer, W., Kretzschmar, H. A., & Poser, S. (2002) · Neurology · doi:10.1212/wnl.58.2.192 · Cited by 289 · see citing works

Differential Diagnosis of Alzheimer Disease With Cerebrospinal Fluid Levels of Tau Protein Phosphorylated at Threonine 231

Büerger, K., Zinkowski, R. P., Teipel, S. J., Tapiola, T., Arai, H., Blennow, K., Andreasen, N., Hofmann‐Kiefer, K., DeBernardis, J. F., Kerkman, D. J., et al. (2002) · Archives of Neurology · doi:10.1001/archneur.59.8.1267 · Cited by 275 · see citing works

CSF Total tau, Aβ42 and Phosphorylated tau Protein as Biomarkers for Alzheimer's Disease

Blennow, K., Vanmechelen, E., & Hampel, H. J. (2001) · Molecular Neurobiology · doi:10.1385/mn:24:1-3:087 · Cited by 263 · see citing works

Large‐scale, multicenter study of cerebrospinal fluid tau protein phosphorylated at serine 199 for the antemortem diagnosis of Alzheimer's disease

Itoh, N., Arai, H., Urakami, K., Ishiguro, K., Ohno, H., Hampel, H., Buerger, K., Wiltfang, J., Otto, M., Kretzschmar, H., et al. (2001) · Annals of Neurology · doi:10.1002/ana.1054 · Cited by 256 · see citing works

Cerebrospinal fluid tau protein as a biochemical marker for Alzheimer's disease: a community based follow up study

Andreasen, N. C., Vanmechelen, E., VOORDE, A. V. D., Davidsson, P., Hesse, C., Tarvonen-Schröder, S., Räihä, I. J., Sourander, L., Winblad, B. G., & Blennow, K. (1998) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.64.3.298 · Cited by 227 · see citing works

Quantification of Axonal Damage in Traumatic Brain Injury

Zemlan, F. P., Rosenberg, W. S., Luebbe, P., Campbell, T. A., Dean, G. E., Weiner, N. E., Cohen, J. A., Rudick, R. A., & Woo, D. (1999) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1999.0720741.x · Cited by 187 · see citing works

Cytoskeleton proteins in CSF distinguish frontotemporal dementia from AD

Sjögren, M., Rosengren, L., Minthon, L., Davidsson, P., Blennow, K., & Wallin, A. (2000) · Neurology · doi:10.1212/wnl.54.10.1960 · Cited by 181 · see citing works

Phosphorylated tau in human cerebrospinal fluid is a diagnostic marker for Alzheimer's disease

Ishiguro, K., Ohno, H., Arai, H., Yamaguchi, H., Urakami, K., Park, J., Sato, K., Kohno, H., & Imahori, K. (1999) · Neuroscience Letters · doi:10.1016/s0304-3940(99)00476-0 · Cited by 175 · see citing works

Detection of tau phosphorylated at threonine 231 in cerebrospinal fluid of Alzheimer's disease patients

Kohnken, R. E., Büerger, K., Zinkowski, R. P., Miller, C., Kerkman, D. J., DeBernardis, J. F., Shen, J., Möller, H., Davies, P., & Hampel, H. J. (2000) · Neuroscience Letters · doi:10.1016/s0304-3940(00)01178-2 · Cited by 173 · see citing works

Tau and Aβ42 protein in CSF of patients with frontotemporal degeneration

Riemenschneider, M. J., Wagenpfeil, S., Diehl, J., Lautenschlager, N. T., Theml, T., Heldmann, B., Drzezga, A. E., Jähn, T., Förstl, H., & Kurz, A. (2002) · Neurology · doi:10.1212/wnl.58.11.1622 · Cited by 167 · see citing works

Increased tau in the cerebrospinal fluid of patients with frontotemporal dementia and Alzheimer's disease

Green, A. J. E., Harvey, R. J., Thompson, E. J., & Rossor, M. N. (1999) · Neuroscience Letters · doi:10.1016/s0304-3940(98)00904-5 · Cited by 166 · see citing works

The τ Protein in Human Cerebrospinal Fluid in Alzheimer's Disease Consists of Proteolytically Derived Fragments

Johnson, G. V. W., Seubert, P., Cox, T. M., Motter, R., Brown, J. P., & Galasko, D. (1997) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1997.68010430.x · Cited by 162 · see citing works

Detection of Proteins in Normal and Alzheimer's Disease Cerebrospinal Fluid with a Sensitive Sandwich Enzyme‐Linked Immunosorbent Assay

Vandermeeren, M., Mercken, M., Vanmechelen, E., Six, J., Voorde, A., Martin, J.-J., & Cras, P. (1993) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1993.tb09823.x · Cited by 145 · see citing works

Accuracy of clinical criteria for AD in the Honolulu–Asia Aging Study, a population-based study

Petrovitch, H., White, L. R., Ross, G. W., Steinhorn, S. C., Li, C. Y., Masaki, K., Davis, D. G., Nelson, J., Hardman, J. M., Curb, J. D., et al. (2001) · Neurology · doi:10.1212/wnl.57.2.226 · Cited by 136 · see citing works

Biomarkers of Alzheimer Disease

Growdon, J. H. (1999) · Archives of Neurology · doi:10.1001/archneur.56.3.281 · Cited by 101 · see citing works

Increased Cerebrospinal Fluid Tau Protein in Multiple Sclerosis

Kapaki, E. N., Paraskevas, G. P., Michalopoulou, M., & Kilidireas, K. (2000) · European Neurology · doi:10.1159/000008181 · Cited by 80 · see citing works

Cerebrospinal fluid tau in dementia disorders: a large scale multicenter study by a Japanese study group

Shoji, M., Matsubara, E., Murakami, T., Manabe, Y., Abe, K., Kanai, M., Ikeda, M., Tomidokoro, Y., Shizuka, M., Watanabe, M., et al. (2002) · Neurobiology of Aging · doi:10.1016/s0197-4580(01)00309-8 · Cited by 74 · see citing works

Neurodegenerative dementias : clinical features and pathological mechanisms

Clark, C. M., & Trojanowski, J. Q. (2000) · McGraw-Hill, Health Professions Division eBooks · Cited by 72 · see citing works

A comparison of tau protein in cerebrospinal fluid between corticobasal degeneration and progressive supranuclear palsy

Urakami, K., Mori, M., Wada, K., Kowa, H., Takeshima, T., Arai, H., Sasaki, H., Kanai, M., Shoji, M., Ikemoto, K., et al. (1999) · Neuroscience Letters · doi:10.1016/s0304-3940(98)00923-9 · Cited by 59 · see citing works

Alzheimer Disease

Emilien, G., Maloteaux, J., Beyreuther, K. T., & Masters, C. L. (2000) · Archives of Neurology · doi:10.1001/archneur.57.2.176 · Cited by 55 · see citing works

Potential Treatment Opportunities for Alzheimer's Disease Through Inhibition of Secretases and Aβ Immunization

Schenk, D., Games, D., & Seubert, P. (2001) · Journal of Molecular Neuroscience · doi:10.1385/jmn:17:2:259 · Cited by 44 · see citing works

Increased cerebrospinal fluid protein tau concentration in neuro-AIDS

Andersson, L., Blennow, K., Fuchs, D., Svennerholm, B., & Gisslén, M. (1999) · Journal of the Neurological Sciences · doi:10.1016/s0022-510x(99)00253-1 · Cited by 44 · see citing works

Amyloid β vaccination: reduced plaques and improved cognition

Younkin, S. G. (2001) · Nature Medicine · doi:10.1038/83929 · Cited by 40 · see citing works

Cerebrospinal fluid levels of A beta 42 and tau: potential markers of Alzheimer's disease.

Galasko, D. R. (1998) · PubMed · Cited by 27 · see citing works

Aβ Modulation: The Next Generation of AD Therapeutics

Felsenstein, K. M. (2000) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2000.tb06935.x · Cited by 8 · see citing works

Aβ-modulation: The next generation of ad therapeutics

Molinoff, P. B., Felsenstein, K. M., Smith, D. W., & Barten, D. M. (2000) · Neurobiology of Aging · doi:10.1016/s0197-4580(00)82412-4 · Cited by 5 · see citing works

Untitled work

(2000) · doi:10.1002/1531-8249(200011)48:5

Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade

Jack, C. R., Knopman, D. S., Jagust, W. J., Shaw, L. M., Aisen, P. S., Weiner, M. W., Petersen, R. C., & Trojanowski, J. Q. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70299-6 · Cited by 4,806 · see citing works

Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects

Shaw, L. M., Vanderstichele, H., Knapik‐Czajka, M., Clark, C. M., Aisen, P. S., Petersen, R. C., Blennow, K., Soares, H., Simon, A., Lewczuk, P., et al. (2009) · Annals of Neurology · doi:10.1002/ana.21610 · Cited by 2,065 · see citing works

Revising the definition of Alzheimer's disease: a new lexicon

Dubois, B., Feldman, H. H., Jacova, C., Cummings, J. L., DeKosky, S. T., Barberger-Gateau, P., Delacourte, A., Frisoni, G., Fox, N. C., Galasko, D., et al. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70223-4 · Cited by 1,869 · see citing works

Cerebrospinal fluid and plasma biomarkers in Alzheimer disease

Blennow, K., Hampel, H., Weiner, M., & Zetterberg, H. (2010) · Nature Reviews Neurology · doi:10.1038/nrneurol.2010.4 · Cited by 1,863 · see citing works

Human ApoE isoforms differentially regulate brain amyloid-β peptide clearance

Castellano, J. M., Kim, J., Stewart, F. R., Jiang, H., DeMattos, R. B., Patterson, B. W., Fagan, A. M., Morris, J. C., Mawuenyega, K. G., Cruchaga, C., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002156 · Cited by 1,227 · see citing works

Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease

Jack, C. R., Lowe, V. J., Weigand, S. D., Wiste, H. J., Senjem, M. L., Knopman, D. S., Shiung, M. M., Gunter, J. L., Boeve, B. F., Kemp, B. J., et al. (2009) · Brain · doi:10.1093/brain/awp062 · Cited by 1,099 · see citing works

Cerebrospinal Fluid β-Amyloid 42 and Tau Proteins as Biomarkers of Alzheimer-Type Pathologic Changes in the Brain

Tapiola, T., Alafuzoff, I., Herukka, S.-K., Parkkinen, L., Hartikainen, P., Soininen, H., & Pirttilä, T. (2009) · Archives of Neurology · doi:10.1001/archneurol.2008.596 · Cited by 896 · see citing works

<i>APOE</i> predicts amyloid‐beta but not tau Alzheimer pathology in cognitively normal aging

Morris, J. C., Roe, C. M., Xiong, C., Fagan, A. M., Goate, A. M., Holtzman, D. M., & Mintun, M. A. (2010) · Annals of Neurology · doi:10.1002/ana.21843 · Cited by 830 · see citing works

Nanoparticle-based detection in cerebral spinal fluid of a soluble pathogenic biomarker for Alzheimer’s disease

Georganopoulou, D. G., Chang, L., Nam, J.-M., Thaxton, C. S., Mufson, E. J., Klein, W. L., & Mirkin, C. A. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0409336102 · Cited by 835 · see citing works

MRI of hippocampal volume loss in early Alzheimer's disease in relation to ApoE genotype and biomarkers

Schuff, N., Woerner, N., Boreta, L., Kornfield, T., Shaw, L. M., Trojanowski, J. Q., Thompson, P. M., Jack, C. R., Weiner, M. W., & Initiative, T. A. D. N. (2008) · Brain · doi:10.1093/brain/awp007 · Cited by 679 · see citing works

Amyloid β concentrations and stable isotope labeling kinetics of human plasma specific to central nervous system amyloidosis

Ovod, V., Ramsey, K. N., Mawuenyega, K. G., Bollinger, J. G., Hicks, T., Schneider, T., Sullivan, M., Paumier, K., Holtzman, D. M., Morris, J. C., et al. (2017) · Alzheimer's &amp; Dementia · doi:10.1016/j.jalz.2017.06.2266 · Cited by 585 · see citing works

Recommendations for the diagnosis and management of Alzheimer's disease and other disorders associated with dementia: EFNS guideline

Waldemar, G., Dubois, B., Emre, M., Georges, J., McKeith, I. G., Rossor, M. N., Scheltens, P., Tariska, P., & Winblad, B. G. (2007) · European Journal of Neurology · doi:10.1111/j.1468-1331.2006.01605.x · Cited by 619 · see citing works

Focal cortical presentations of Alzheimer's disease

Alladi, S., Xuereb, J., Bak, T., Nestor, P., Knibb, J., Patterson, K., & Hodges, J. R. (2007) · Brain · doi:10.1093/brain/awm213 · Cited by 581 · see citing works

BrainAGE in Mild Cognitive Impaired Patients: Predicting the Conversion to Alzheimer’s Disease

Gaser, C., Franke, K., Klöppel, S., Koutsouleris, N., Sauer, H., & Initiative, A. D. N. (2013) · PLoS ONE · doi:10.1371/journal.pone.0067346 · Cited by 537 · see citing works

Brain beta-amyloid measures and magnetic resonance imaging atrophy both predict time-to-progression from mild cognitive impairment to Alzheimer's disease

Jack, C. R., Wiste, H. J., Vemuri, P., Weigand, S. D., Senjem, M. L., Zeng, G., Bernstein, M. A., Gunter, J. L., Pankratz, V. S., Aisen, P. S., et al. (2010) · Brain · doi:10.1093/brain/awq277 · Cited by 531 · see citing works

sTREM2 cerebrospinal fluid levels are a potential biomarker for microglia activity in early‐stage Alzheimer's disease and associate with neuronal injury markers

Suárez‐Calvet, M., Kleinberger, G., Araque Caballero, M. Á., Brendel, M., Rominger, A., Alcolea, D., Fortea, J., Lleó, A., Blesa, R., Gispert, J. D., et al. (2016) · EMBO Molecular Medicine · doi:10.15252/emmm.201506123 · Cited by 522 · see citing works

Pittsburgh compound B imaging and prediction of progression from cognitive normality to symptomatic Alzheimer disease

Morris, J. C., Roe, C. M., Grant, E. A., Head, D., Storandt, M., Goate, A. M., Fagan, A. M., Holtzman, D. M., & Mintun, M. A. (2009) · Archives of Neurology · doi:10.1001/archneurol.2009.269 · Cited by 476 · see citing works

Clinical utility of cerebrospinal fluid biomarkers in the diagnosis of early Alzheimer's disease

Blennow, K., Dubois, B., Fagan, A. M., Lewczuk, P., de Leon, M. J., & Hampel, H. J. (2014) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2014.02.004 · Cited by 455 · see citing works

Alzheimer’s Disease

de Paula, V. D. J. R., Radanovic, M., Diniz, B. S., & Forlenza, O. V. (2012) · Sub-cellular biochemistry/Subcellular biochemistry · doi:10.1007/978-94-007-5416-4_14 · Cited by 444 · see citing works

Longitudinal Change in CSF Biomarkers in Autosomal-Dominant Alzheimer’s Disease

Fagan, A. M., Xiong, C., Jasielec, M. S., Bateman, R. J., Goate, A. M., Benzinger, T. L. S., Ghetti, B., Martins, R. N., Masters, C. L., Mayeux, R., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3007901 · Cited by 434 · see citing works

Decreased α-synuclein in cerebrospinal fluid of aged individuals and subjects with Parkinson’s disease

Tokuda, T., Salem, S. A., Allsop, D., Mizuno, T., Nakagawa, M., Qureshi, M. M., Locascio, J. J., Schlossmacher, M. G., & El-Agnaf, O. M. A. (2006) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2006.08.024 · Cited by 425 · see citing works

Diversity and Disparity in Dementia: The Impact of Ethnoracial Differences in Alzheimer Disease

Chin, A. L., Negash, S., & Hamilton, R. (2011) · Alzheimer Disease &amp; Associated Disorders · doi:10.1097/wad.0b013e318211c6c9 · Cited by 416 · see citing works

MRI and CSF biomarkers in normal, MCI, and AD subjects

Vemuri, P., Wiste, H. J., Weigand, S. D., Shaw, L. M. J., Trojanowski, J. Q., Weiner, M. W., Knopman, D. S., Petersen, R. C., & Jack, C. R. (2009) · Neurology · doi:10.1212/wnl.0b013e3181af79fb · Cited by 398 · see citing works

CSF amyloid β 1-42 predicts cognitive decline in Parkinson disease

Siderowf, A. D., Xie, S. X., Hurtig, H. I., Weintraub, D. A., Duda, J. E., Chen‐Plotkin, A. S., Shaw, L. M. J., Deerlin, V. M. V., Trojanowski, J. Q., & Clark, C. N. (2010) · Neurology · doi:10.1212/wnl.0b013e3181f39a78 · Cited by 379 · see citing works

Biomarkers of neurodegeneration for diagnosis and monitoring therapeutics

Shaw, L. M. J., Korecka, M., Clark, C. M., Lee, V. M. ‐., & Trojanowski, J. Q. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2176 · Cited by 339 · see citing works

Alzheimer's Disease and Mild Cognitive Impairment

Kelley, B. J., & Petersen, R. C. (2007) · Neurologic Clinics · doi:10.1016/j.ncl.2007.03.008 · Cited by 328 · see citing works

Qualification of the analytical and clinical performance of CSF biomarker analyses in ADNI

Initiative, T. A. D. N., Shaw, L. M. J., Vanderstichele, H., Knapik-Czajka, M. E., Figurski, M., Coart, E., Blennow, K., Soares, H. D., Simon, A. J., Lewczuk, P., et al. (2011) · Acta Neuropathologica · doi:10.1007/s00401-011-0808-0 · Cited by 297 · see citing works

Nanotechnologies for Alzheimer's disease: diagnosis, therapy, and safety issues

Brambilla, D., Droumaguet, B. L., Nicolas, J., Hashemi, S. H., Wu, L., Moghimi, S. M., Couvreur, P., & Andrieux, K. (2011) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2011.03.008 · Cited by 293 · see citing works

CSF tau/Aβ 42 ratio for increased risk of mild cognitive impairment

Li, G., Sokal, I., Quinn, J. F., Leverenz, J. B., Brodey, M., Schellenberg, G. D., Kaye, J. A., Raskind, M. A., Zhang, J., Peskind, E. R., et al. (2007) · Neurology · doi:10.1212/01.wnl.0000267428.62582.aa · Cited by 274 · see citing works

Diagnostic performance of a CSF-biomarker panel in autopsy-confirmed dementia

Engelborghs, S., de Vreese, K., de Casteele, T. V., Vanderstichele, H., Everbroeck, B. V., Cras, P. P., Martin, J., Vanmechelen, E., & Deyn, P. P. D. (2007) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2007.02.016 · Cited by 256 · see citing works

Diagnosis of Alzheimer’s disease utilizing amyloid and tau as fluid biomarkers

Lee, J. C., Kim, S. J., Hong, S., & Kim, Y. (2019) · Experimental &amp; Molecular Medicine · doi:10.1038/s12276-019-0250-2 · Cited by 253 · see citing works

Alzheimer Disease

Apostolova, L. G. (2016) · CONTINUUM Lifelong Learning in Neurology · doi:10.1212/con.0000000000000307 · Cited by 253 · see citing works

MRI and CSF biomarkers in normal, MCI, and AD subjects

Vemuri, P., Wiste, H. J., Weigand, S. D., Shaw, L. M. J., Trojanowski, J. Q., Weiner, M. W., Knopman, D. S., Petersen, R. C., & Jack, C. R. (2009) · Neurology · doi:10.1212/wnl.0b013e3181af79e5 · Cited by 246 · see citing works

Alzheimer neurofibrillary degeneration: significance, etiopathogenesis, therapeutics and prevention

Iqbal, K., & Grundke, I. (2008) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2008.00225.x · Cited by 238 · see citing works

Plasma multianalyte profiling in mild cognitive impairment and Alzheimer disease

Hu, W. T., Holtzman, D. M., Fagan, A. M., Shaw, L. M. J., Perrin, R. J., Arnold, S. E., Grossman, M., Xiong, C., Craig‐Schapiro, R., Clark, C. M., et al. (2012) · Neurology · doi:10.1212/wnl.0b013e318266fa70 · Cited by 234 · see citing works

Early diagnosis of Alzheimer’s disease: the role of biomarkers including advanced EEG signal analysis. Report from the IFCN-sponsored panel of experts

Rossini, P. M., Iorio, R. D., Vecchio, F., Anfossi, M., Babiloni, C., Bozzali, M., Bruni, A. C., Cappa, S. F., Escudero, J., Fraga, F. J., et al. (2020) · Clinical Neurophysiology · doi:10.1016/j.clinph.2020.03.003 · Cited by 239 · see citing works

Sex and age differences in atrophic rates: an ADNI study with n=1368 MRI scans

Hua, X., Hibar, D. P., Lee, S., Toga, A. W., Jack, C. R., Weiner, M. W., & Thompson, P. M. (2010) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2010.04.033 · Cited by 234 · see citing works

The Role of Biomarkers in Clinical Trials for Alzheimer Disease

Thal, L. J., Kantarci, K., Reiman, E. M., Klunk, W. E., Weiner, M. W., Zetterberg, H., Galasko, D., Praticò, D., Griffin, S. T., Schenk, D., et al. (2006) · Alzheimer Disease & Associated Disorders · doi:10.1097/01.wad.0000191420.61260.a8 · Cited by 233 · see citing works

Cerebrospinal fluid profile in frontotemporal dementia and Alzheimer’s disease

Grossman, M., Farmer, J., Leight, S., Work, M., Moore, P., Van Deerlin, V., Pratico, D., Clark, C. M., Coslett, H. B., Chatterjee, A., et al. (2005) · Annals of Neurology · doi:10.1002/ana.20477 · Cited by 228 · see citing works

Alzheimer's disease biomarker discovery using SOMAscan multiplexed protein technology

Sattlecker, M., Kiddle, S. J., Newhouse, S., Proitsi, P., Nelson, S., Williams, S., Johnston, C., Killick, R., Simmons, A., Westman, E., et al. (2014) · Alzheimer's &amp; Dementia · doi:10.1016/j.jalz.2013.09.016 · Cited by 223 · see citing works

Evidence for Ordering of Alzheimer Disease Biomarkers

Jack, C. R. (2011) · Archives of Neurology · doi:10.1001/archneurol.2011.183 · Cited by 221 · see citing works

Low cerebrospinal fluid concentration of mitochondrial DNA in preclinical Alzheimer disease

Podlesniy, P., Figueiro‐Silva, J., Llado, A., Antonell, A., Sanchez‐Valle, R., Alcolea, D., Lleo, A., Molinuevo, J. L., Serra, N., & Trullas, R. (2013) · Annals of Neurology · doi:10.1002/ana.23955 · Cited by 219 · see citing works

Biomarkers of Alzheimer's disease

Craig‐Schapiro, R., Fagan, A. M., & Holtzman, D. M. (2008) · Neurobiology of Disease · doi:10.1016/j.nbd.2008.10.003 · Cited by 217 · see citing works

CSF biomarkers in frontotemporal lobar degeneration with known pathology

Bian, H., Van Swieten, J. C., Leight, S., Massimo, L., Wood, E., Forman, M., Moore, P., de Koning, I., Clark, C. M., Rosso, S., et al. (2008) · Neurology · doi:10.1212/01.wnl.0000311445.21321.fc · Cited by 216 · see citing works

Fluid Biomarkers in Alzheimer Disease

Blennow, K., Zetterberg, H., & Fagan, A. M. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006221 · Cited by 208 · see citing works

Alzheimer disease: new concepts on its neurobiology and the clinical role imaging will play

Jack, C. R. (2012) · Radiology · doi:10.1148/radiol.12110433 · Cited by 211 · see citing works

3D-Deep Learning Based Automatic Diagnosis of Alzheimer’s Disease with Joint MMSE Prediction Using Resting-State fMRI

Duc, N. T., Ryu, S., Qureshi, M. N. I., Choi, M., Lee, K. H., & Lee, B. (2019) · Neuroinformatics · doi:10.1007/s12021-019-09419-w · Cited by 202 · see citing works

Comparative proteomics of cerebrospinal fluid in neuropathologically-confirmed Alzheimer's disease and non-demented elderly subjects

Castaño, E. M., Roher, A. E., Esh, C. L., Kokjohn, T. A., & Beach, T. G. (2006) · Neurological Research · doi:10.1179/016164106x98035 · Cited by 201 · see citing works

Novel CSF biomarkers for Alzheimer’s disease and mild cognitive impairment

Hu, W. T., Chen‐Plotkin, A. S., Arnold, S. E., Grossman, M., Clark, C. M., Shaw, L. M. J., Pickering, E. H., Kühn, M., Chen, Y., McCluskey, L. F., et al. (2010) · Acta Neuropathologica · doi:10.1007/s00401-010-0667-0 · Cited by 196 · see citing works

Cerebrospinal fluid biomarkers in the differential diagnosis of Alzheimer's disease from other cortical dementias

de Souza, L. C., Lamari, F., Belliard, S., Jardel, C., Houillier, C., Paz, R. D., Dubois, B., & Sarazin, M. (2010) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.2010.207183 · Cited by 190 · see citing works

Cerebrospinal fluid proteomic biomarkers for Alzheimer's disease

Finehout, E. J., Franck, Z., Choe, L. H., Relkin, N. R., & Lee, K. H. (2006) · Annals of Neurology · doi:10.1002/ana.21038 · Cited by 185 · see citing works

CSF biomarkers cutoffs: The importance of coincident neuropathological diseases

Toledo, J. B., Brettschneider, J., Grossman, M., Arnold, S. E., Hu, W. T., Xie, S. X., Lee, V. M.-Y., Shaw, L. M., & Trojanowski, J. Q. (2012) · Acta Neuropathologica · doi:10.1007/s00401-012-0983-7 · Cited by 182 · see citing works

Alzheimer's Disease Neuroimaging Initiative: A one-year follow up study using tensor-based morphometry correlating degenerative rates, biomarkers and cognition

Leow, A. D., Yanovsky, I., Parikshak, N., Hua, X., Lee, S., Toga, A. W., Jack, C. R., Bernstein, M. A., Britson, P. J., Gunter, J. L., et al. (2009) · NeuroImage · doi:10.1016/j.neuroimage.2009.01.004 · Cited by 180 · see citing works

PET amyloid-beta imaging in preclinical Alzheimer's disease

Vlassenko, A. G., Benzinger, T. L. S., & Morris, J. C. (2011) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2011.11.005 · Cited by 173 · see citing works

Do CSF total tau, phosphorylated tau, and β-amyloid 42 help to predict progression of mild cognitive impairment to Alzheimer's disease? A systematic review and meta-analysis of the literature

Diniz, B. S., Pinto, J. A., & Forlenza, O. V. (2008) · The World Journal of Biological Psychiatry · doi:10.1080/15622970701535502 · Cited by 168 · see citing works

Tau and p-tau as CSF biomarkers in dementia: a meta-analysis

van Harten, A. C., Kester, M. I., Visser, P. J., Blankenstein, M. A., Pijnenburg, Y. A. L., van der Flier, W. M., & Scheltens, P. (2011) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm.2011.086 · Cited by 164 · see citing works

Quantitative analysis of amyloid β peptides in cerebrospinal fluid of Alzheimer's disease patients by immunoaffinity purification and stable isotope dilution liquid chromatography/negative electrospray ionization tandem mass spectrometry

Oe, T., Ackermann, B. L., Inoue, K., Berna, M. J., Garner, C. O., Gelfanova, V., Dean, R. A., Siemers, E., Holtzman, D. M., Farlow, M. R., et al. (2006) · Rapid Communications in Mass Spectrometry · doi:10.1002/rcm.2787 · Cited by 166 · see citing works

Subcellular and metabolic examination of amyloid-β peptides in Alzheimer disease pathogenesis: Evidence for Aβ25–35

Kaminsky, Y. G., Marlatt, M. W., Smith, M. A., & Kosenko, E. A. (2009) · Experimental Neurology · doi:10.1016/j.expneurol.2009.09.005 · Cited by 165 · see citing works

Development and evaluation of a multiplexed mass spectrometry based assay for measuring candidate peptide biomarkers in Alzheimer's Disease Neuroimaging Initiative (ADNI) CSF

Spellman, D. S., Wildsmith, K. R., Honigberg, L. A., Tuefferd, M., Baker, D., Raghavan, N., Nairn, A. C., Croteau, P., Schirm, M., Allard, R., et al. (2015) · PROTEOMICS – Clinical Applications · doi:10.1002/prca.201400178 · Cited by 161 · see citing works

Impact of chronic Helicobacter pylori infection on Alzheimer's disease: preliminary results

Baudron, C. R., Krolak‐Salmon, P., Quadrio, I., Mégraud, F., & Salles, N. (2011) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2011.10.021 · Cited by 152 · see citing works

Stem Cell-Derived Exosomes: a New Strategy of Neurodegenerative Disease Treatment

Hosseini, N. F., Sheykhhasan, M., Asl, S. S., & Najafi, R. (2021) · Molecular Neurobiology · doi:10.1007/s12035-021-02324-x · Cited by 153 · see citing works

Biomarkers used in Alzheimer’s disease diagnosis, treatment, and prevention

Mahaman, Y. A. R., Embaye, K. S., Huang, F., Li, L., Zhu, F., Wang, J.-Z., Liu, R., Feng, J., & Wang, X. (2022) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101544 · Cited by 149 · see citing works

The dynamics of Alzheimer's disease biomarkers in the Alzheimer's Disease Neuroimaging Initiative cohort

Caroli, A., & Frisoni, G. B. (2010) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2010.04.024 · Cited by 146 · see citing works

Diagnosis and biomarkers of predementia in Alzheimer's disease

Forlenza, O. V., Diniz, B. S., & Gattaz, W. F. (2010) · BMC Medicine · doi:10.1186/1741-7015-8-89 · Cited by 145 · see citing works

A randomized, controlled clinical trial of plasma exchange with albumin replacement for Alzheimer's disease: Primary results of the AMBAR Study

Boada, M., López, O. L., Olazarán, J., Núñez, L., Pfeffer, M., Paricio, M., Lorites, J., Piñol‐Ripoll, G., Gámez, J. E., Anaya, F., et al. (2020) · Alzheimer's &amp; Dementia · doi:10.1002/alz.12137 · Cited by 143 · see citing works

CSF biomarker levels in early and late onset Alzheimer's disease

Bouwman, F. H., Schoonenboom, N. S. M., Verwey, N. A., van Elk, E. J., Kok, A., Blankenstein, M. A., Scheltens, P., & van der Flier, W. M. (2008) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2008.02.007 · Cited by 142 · see citing works

Identification of longitudinally dynamic biomarkers in Alzheimer’s disease cerebrospinal fluid by targeted proteomics

Wildsmith, K. R., Schauer, S. P., Smith, A. M., Arnott, D. P., Zhu, Y., Haznedar, J., Kaur, S., Mathews, W. R., & Honigberg, L. A. (2014) · Molecular Neurodegeneration · doi:10.1186/1750-1326-9-22 · Cited by 140 · see citing works

Biomarkers for Alzheimer's disease therapeutic trials

Hampel, H. J., Wilcock, G. K., Andrieu, S., Aisen, P. S. S., Blennow, K., Broich, K., Carrillo, M. C., Fox, N. C., Frisoni, G. B., Isaac, M., et al. (2010) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2010.11.005 · Cited by 137 · see citing works

3D PIB and CSF biomarker associations with hippocampal atrophy in ADNI subjects

Apostolova, L. G., Hwang, K., Andrawis, J. P., Green, A. E., Babakchanian, S., Morra, J. H., Cummings, J. L., Toga, A. W., Trojanowski, J. Q., Shaw, L. M. J., et al. (2010) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2010.05.003 · Cited by 137 · see citing works

Dementia risk and prevention by targeting modifiable vascular risk factors

Tariq, S., & Barber, P. A. (2017) · Journal of Neurochemistry · doi:10.1111/jnc.14132 · Cited by 135 · see citing works

CSF biomarkers for the differential diagnosis of Alzheimer's disease: A large‐scale international multicenter study

Ewers, M., Mattsson, N., Minthon, L., Molinuevo, J. L., Antonell, A., Popp, J., Jessen, F., Herukka, S., Soininen, H., Maetzler, W., et al. (2015) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2014.12.006 · Cited by 133 · see citing works

Clinical validity of cerebrospinal fluid Aβ42, tau, and phospho-tau as biomarkers for Alzheimer's disease in the context of a structured 5-phase development framework

Mattsson, N., Lönneborg, A., Boccardi, M., Blennow, K., & Hansson, O. (2017) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2016.02.034 · Cited by 134 · see citing works

Exosomes in Pathogenesis, Diagnosis, and Treatment of Alzheimer’s Disease

Jiang, L., Dong, H., Cao, H., Ji, X., Luan, S., & Liu, J. (2019) · Medical Science Monitor · doi:10.12659/msm.914027 · Cited by 128 · see citing works

Immunotherapy for Alzheimer‘s Disease: From Anti-β-Amyloid to Tau-Based Immunization Strategies

Panza, F., Frisardi, V., Solfrizzi, V., Imbimbo, B. P., Logroscino, G., Santamato, A., Greco, A., Seripa, D., & Pilotto, A. (2012) · Immunotherapy · doi:10.2217/imt.11.170 · Cited by 125 · see citing works

Tau as a Biomarker of Neurodegenerative Diseases

Schraen‐Maschke, S., Sergeant, N., Dhaenens, C., Bombois, S., Deramecourt, V., Caillet‐Boudin, M., Pasquier, F., Maurage, C., Sablonnière, B., Vanmechelen, E., et al. (2008) · Biomarkers in Medicine · doi:10.2217/17520363.2.4.363 · Cited by 121 · see citing works

CSF phosphorylated tau in the diagnosis and prognosis of mild cognitive impairment and Alzheimer's disease: a meta-analysis of 51 studies

Mitchell, A. J. (2009) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.2008.167791 · Cited by 123 · see citing works

Biomarkers in Alzheimer's disease drug development

Cummings, J. L. (2011) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2010.06.004 · Cited by 121 · see citing works

Future Therapeutic Perspectives into the Alzheimer’s Disease Targeting the Oxidative Stress Hypothesis

Teixeira, J. P., de Castro, A. A., Soares, F. V., da Cunha, E. F. F., & Ramalho, T. C. (2019) · Molecules · doi:10.3390/molecules24234410 · Cited by 122 · see citing works

Novel targets for Alzheimer's disease treatment

Grill, J., & Cummings, J. (2010) · Expert Review of Neurotherapeutics · doi:10.1586/ern.10.29 · Cited by 113 · see citing works

Harmonized diagnostic criteria for Alzheimer's disease: recommendations

Morris, J. C., Blennow, K., Froelich, L., Nordberg, A. K., Soininen, H. S., Waldemar, G., Wahlund, L., & Dubois, B. (2014) · Journal of Internal Medicine · doi:10.1111/joim.12199 · Cited by 120 · see citing works

Mapping correlations between ventricular expansion and CSF amyloid and tau biomarkers in 240 subjects with Alzheimer's disease, mild cognitive impairment and elderly controls

Chou, Y.-Y., Leporé, N., Avedissian, C., Madsen, S. K., Parikshak, N., Hua, X., Shaw, L. M., Trojanowski, J. Q., Weiner, M. W., Toga, A. W., et al. (2009) · NeuroImage · doi:10.1016/j.neuroimage.2009.02.015 · Cited by 117 · see citing works

Spatial patterns of brain amyloid- burden and atrophy rate associations in mild cognitive impairment

Tosun, D., Schuff, N. W., Mathis, C. A., Jagust, W., Weiner, M. W., & Initiative, A. D. N. (2011) · Brain · doi:10.1093/brain/awr044 · Cited by 117 · see citing works

Upcoming Candidate Cerebrospinal Fluid Biomarkers of Alzheimer’s Disease

Fagan, A. M., & Perrin, R. J. (2012) · Biomarkers in Medicine · doi:10.2217/bmm.12.42 · Cited by 115 · see citing works

Comparison of Cerebrospinal Fluid Levels of Tau and Aβ 1-42 in Alzheimer Disease and Frontotemporal Degeneration Using 2 Analytical Platforms

Irwin, D. J., McMillan, C. T., Toledo, J. B., Arnold, S. E., Shaw, L. M., Wang, L.-S., Van Deerlin, V., Lee, V. M.-Y., Trojanowski, J. Q., & Grossman, M. (2012) · Archives of Neurology · doi:10.1001/archneurol.2012.26 · Cited by 116 · see citing works

Brain Ventricular Volume and Cerebrospinal Fluid Biomarkers of Alzheimer's Disease

Ott, B. R., Initiative, T. A. D. N., Cohen, R. A., Gongvatana, A., Okonkwo, O. C., Johanson, C. E., Stopa, E. G., Donahue, J. E., & Silverberg, G. D. (2010) · Journal of Alzheimer s Disease · doi:10.3233/jad-2010-1406 · Cited by 113 · see citing works

Plasma levels of beta-amyloid (1–42) in Alzheimer's disease and mild cognitive impairment

Pesaresi, M., Lovati, C., Bertora, P., Mailland, E., Galimberti, D., Scarpini, E. A., Quadri, P., Forloni, G., & Mariani, C. B. (2006) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2006.03.004 · Cited by 111 · see citing works

Proteomics-derived cerebrospinal fluid markers of autopsy-confirmed Alzheimer’s disease

Roher, A. E., Maarouf, C. L., Sue, L. I., Hu, Y., Wilson, J. R., & Beach, T. G. (2009) · Biomarkers · doi:10.3109/13547500903108423 · Cited by 108 · see citing works

Dementia syndromes: evaluation and treatment

Scott, K. R., & Barrett, A. M. (2007) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.7.4.407 · Cited by 107 · see citing works

CSF Aβ42, Tau and phosphorylated Tau, APOE ɛ4 allele and MCI type in progressive MCI

Herukka, S., Helisalmi, S., Hallikainen, M., Tervo, S., Soininen, H. S., & Pirttilä, T. (2006) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2006.02.001 · Cited by 109 · see citing works

CSF and MRI markers independently contribute to the diagnosis of Alzheimer's disease

Schoonenboom, N. S. M., van der Flier, W. M., Blankenstein, M. A., Bouwman, F. H., van Kamp, G. J., Barkhof, F., & Scheltens, P. (2007) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2006.11.018 · Cited by 106 · see citing works

CSF biomarkers in relationship to cognitive profiles in Alzheimer disease

van der Vlies, A. E., Verwey, N. A., Bouwman, F. H., Blankenstein, M. A., Klein, M., Scheltens, P., & van der Flier, W. M. (2009) · Neurology · doi:10.1212/01.wnl.0000345014.48839.71 · Cited by 106 · see citing works

A Blood Gene Expression Marker of Early Alzheimer's Disease

Lunnon, K., Sattlecker, M., Furney, S. J., Coppola, G., Simmons, A., Proitsi, P., Lupton, M. K., Lourdusamy, A., Johnston, C., Soininen, H. S., et al. (2013) · Journal of Alzheimer s Disease · doi:10.3233/jad-2012-121363 · Cited by 103 · see citing works

CSF biomarker changes precede symptom onset of mild cognitive impairment

Moghekar, A., Li, S., Lu, Y., Li, M., Wang, M.-C., Albert, M., O’Brien, R., & For the BIOCARD Research Team (2013) · Neurology · doi:10.1212/01.wnl.0000435558.98447.17 · Cited by 103 · see citing works

Comparison of Electrodiagnostic Abnormalities and Criteria in a Cohort of Patients With Chronic Inflammatory Demyelinating Polyneuropathy

Magda, P., Latov, N., Brannagan, T. H., Weimer, L. H., Chin, R. L., & Sander, H. W. (2003) · Archives of Neurology · doi:10.1001/archneur.60.12.1755 · Cited by 100 · see citing works

Effects of acetylcholinesterase inhibitors and memantine on resting-state electroencephalographic rhythms in Alzheimer’s disease patients

Babiloni, C., Percio, C. D., Bordet, R., Bourriez, J., Bentivoglio, M., Payoux, P., Derambure, P., Dix, S. L., Infarinato, F., Lizio, R., et al. (2012) · Clinical Neurophysiology · doi:10.1016/j.clinph.2012.09.017 · Cited by 97 · see citing works

Cerebrospinal Fluid Amyloid ss42/Phosphorylated Tau Ratio Discriminates Between Alzheimer's Disease and Vascular Dementia

de Jong, D., Jansen, R. W. M. M., Kremer, B. P. H., & Verbeek, M. M. (2006) · The Journals of Gerontology Series A: Biological Sciences and Medical Sciences · doi:10.1093/gerona/61.7.755 · Cited by 98 · see citing works

Relations between brain tissue loss, CSF biomarkers, and the ApoE genetic profile: a longitudinal MRI study

Tosun, D., Schuff, N. W., Truran‐Sacrey, D., Shaw, L. M. J., Trojanowski, J. Q., Aisen, P. S. S., Peterson, R., & Weiner, M. W. (2010) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2010.04.030 · Cited by 99 · see citing works

Oxidative signature of cerebrospinal fluid from mild cognitive impairment and Alzheimer disease patients

Di Domenico, F., Pupo, G., Giraldo, E., Badìa, M.-C., Monllor, P., Lloret, A., Eugenia Schininà, M., Giorgi, A., Cini, C., Tramutola, A., et al. (2016) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2015.12.004 · Cited by 97 · see citing works

Cerebrospinal fluid biomarkers for differentiation of frontotemporal lobar degeneration from Alzheimer's disease

Irwin, D. J., Trojanowski, J. Q., & Grossman, M. (2013) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2013.00006 · Cited by 96 · see citing works

Transforming cerebrospinal fluid Aβ42 measures into calculated Pittsburgh compound B units of brain Aβ amyloid

Weigand, S. D., Vemuri, P., Wiste, H. J., Senjem, M. L., Pankratz, V. S., Aisen, P. S., Weiner, M. W., Petersen, R. C., Shaw, L. M., Trojanowski, J. Q., et al. (2011) · Alzheimer's &amp; Dementia · doi:10.1016/j.jalz.2010.08.230 · Cited by 93 · see citing works

The comparison of cerebrospinal fluid levels of tau protein and β-amyloid peptide1-42 in the patients with Alzheimer's disease and those with vascular dementia

Yi, L., 张中兴, 吕路线, 郝伟, & 丁新生 (2004) · doi:10.3760/j:issn:1006-7884.2004.04.007

Decreased β-Amyloid_1-42and Increased Tau Levels in Cerebrospinal Fluid of Patients With Alzheimer Disease

Sunderland, T., Linker, G., Mirza, N., Putnam, K. T., Friedman, D. L., Kimmel, L. H., Bergeson, J., Manetti, G. J., Zimmermann, M., Tang, B., et al. (2003) · JAMA · doi:10.1001/jama.289.16.2094 · Cited by 656 · see citing works

CSF tau protein andβ‐amyloid (1–42) in Alzheimer's disease diagnosis: discrimination from normal ageing and other dementias in the Greek population

Kapaki, E., Paraskevas, G. P., Zalonis, I., & Zournas, C. (2003) · European Journal of Neurology · doi:10.1046/j.1468-1331.2003.00562.x · Cited by 76 · see citing works

Cerebrospinal fluid biochemical markers in early detection and in differential diagnosis of dementia disorders in routine clinical practice

Parnetti, L., Lanari, A., Saggese, E., Spaccatini, C., & Gallai, V. (2003) · Neurological Sciences · doi:10.1007/s10072-003-0129-8 · Cited by 21 · see citing works

Simultaneous assay of CSF levels of tau and Aβ1-42 to the diagnosis of Alzheimer's disease

Yi, W. (2003) · Zhongguo shenjing kexue zazhi